中信博（688408.SH）2025 年一季报点评 盈利能力维持稳定，在手订单增长显著 2025 年 05 月 03 日 ➢ 事件 2025 年 4 月 29 日，公司发布 2025 年一季报。根据公司公告，2025Q1 公司实 现收入 15.59 亿元，同比-14.09%，环比-48.80%，实现归母净利润 1.10 亿元， 同比-28.46%，环比-46.06%，扣非归母净利润 1.00 亿元，同比-29.64%，环比 -47.85%。 ➢ 盈利能力维持稳定 25Q1 公司毛利率、净利率分别为 18.90%、6.83%，环比分别+1.74Pcts、- 0.11Pcts，总体维持稳定。25Q1 期间费用率为 12.31%，环比有所提升，其中销 售、管理、研发、财务费用率分别为 3.44%、5.54%、3.07%、0.26%，分别环 比提升 1.09Pcts、3.23Pcts、0.62Pcts、0.62Pcts，我们认为期间费用率提升主 要由于公司海外市场开拓所致。 ➢ 在手订单显著提升 截至公告披露日，公司在手订单合计 74 亿元，分拆来看，其中跟踪支架在手订 单 52 亿元，占在手订单量的 70.27%， ...

Investment Rating - The report maintains a "Buy" rating for the company, indicating a positive outlook for its stock performance relative to the benchmark index [5][7]. Core Insights - The company reported a revenue of 1.137 billion yuan for 2024, reflecting a year-on-year growth of 2.89%. The net profit attributable to shareholders was 229 million yuan, down 5.43% from the previous year [1]. - In Q1 2025, the company achieved a revenue of 282 million yuan, a year-on-year increase of 2.18%, with a net profit of 53 million yuan, up 1.54% [1]. - The automotive sector's steady growth has positively impacted the company's main business, with domestic operations contributing to revenue growth [2]. Financial Performance - The company's gross margin for 2024 was 35.16%, with a net profit margin of 20.14%. In Q1 2025, these figures were 32.91% and 18.80%, respectively [3]. - The company maintained stable expense ratios in 2024, with sales, management, and financial expense ratios at 2.06%, 5.69%, and -0.92%, respectively [3]. - R&D expense ratio for 2024 was 4.38%, showing a slight decline of 0.11 percentage points year-on-year [3]. Market Opportunities - The self-lubricating bearing industry is expected to expand significantly, with potential applications in construction and robotics. The company is focusing on self-lubricating bearings and screw products for humanoid robots, which are already in small-scale production [4]. - The company is positioned as a leader in the domestic self-lubricating bearing industry, with robust growth in automotive and engineering machinery sectors, and emerging opportunities in humanoid robotics [5]. Profit Forecast - The company is projected to achieve revenues of 1.293 billion yuan, 1.487 billion yuan, and 1.733 billion yuan for 2025, 2026, and 2027, respectively. The net profit attributable to shareholders is expected to be 266 million yuan, 311 million yuan, and 368 million yuan for the same years [5].

证券研究报告·公司点评报告·汽车零部件 星宇股份（601799） 2025 年一季报点评：2025Q1 业绩符合预期， 车灯龙头持续成长 买入（维持） | [Table_EPS] 盈利预测与估值 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业总收入（百万元） | 10,248 | 13,253 | 16,305 | 19,715 | 23,530 | | 同比（%） | 24.25 | 29.32 | 23.03 | 20.91 | 19.35 | | 归母净利润（百万元） | 1,102 | 1,408 | 1,761 | 2,189 | 2,683 | | 同比（%） | 17.07 | 27.78 | 25.02 | 24.31 | 22.60 | | EPS-最新摊薄（元/股） | 3.86 | 4.93 | 6.16 | 7.66 | 9.39 | | P/E（现价&最新摊薄） | 34.37 | 26.90 | 21.52 | 17.31 | 14.12 | [Table_Ta ...

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Views - The company's Q1 2025 performance met expectations, with a significant year-on-year increase in net profit [7] - Revenue for Q1 2025 was 5.037 billion yuan, a year-on-year decrease of 4.73% and a quarter-on-quarter decrease of 5.84% [7] - The net profit attributable to the parent company for Q1 2025 was 104 million yuan, representing a substantial year-on-year growth of 447.56% and a turnaround from losses in the previous quarter [7] - The integration of the Grammer business is progressing steadily, with the company focusing on the passenger car seat assembly business, which is expected to enhance its market share in the long term [7] Financial Forecasts - The company forecasts total revenue of 24.303 billion yuan for 2025, with a year-on-year growth of 9.20% [1] - The net profit attributable to the parent company is projected to be 646.47 million yuan in 2025, with a significant year-on-year increase of 214.06% [1] - The earnings per share (EPS) for 2025 is estimated at 0.51 yuan, with a price-to-earnings (P/E) ratio of 24.25 [1][8]

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Views - The company reported a revenue of 5.834 billion yuan in Q1 2025, a year-on-year decline of 38.55%, with a net profit attributable to shareholders of 431 million yuan, down 39.87% year-on-year [5][6] - The decline in revenue is attributed to external factors such as contract signing progress and supply chain issues, but ongoing fundraising projects are expected to enhance the company's capabilities in weaponry and equipment construction [6] - The company aims to complete its annual tasks in 2025, which is a critical year in the "14th Five-Year Plan," with projected net profits for 2025-2027 of 3.743 billion yuan, 4.323 billion yuan, and 5.051 billion yuan, representing year-on-year growth rates of 10.3%, 15.5%, and 16.8% respectively [7] Financial Summary - The total market capitalization of the company is 117.6 billion yuan, with a closing price of 42.66 yuan [2] - The company’s revenue for 2024 is projected at 42.837 billion yuan, with a year-on-year decrease of 7.4%, followed by a recovery with expected growth of 10.0% in 2025 [9] - The projected P/E ratios for 2025, 2026, and 2027 are 31.41, 27.19, and 23.27 respectively, indicating a potential for valuation improvement over the forecast period [7][9]

Investment Rating - The report maintains a "Buy" rating for Agricultural Bank of China (601288.SH) with a current price of 5.42 CNY [1]. Core Insights - Agricultural Bank of China reported a revenue of 186.7 billion CNY for Q1 2025, with a year-on-year growth rate of 0.4%, and a net profit attributable to shareholders of 71.9 billion CNY, reflecting a 2.2% increase year-on-year [4][5]. - The bank's net interest margin (NIM) was 1.34%, showing a decline of 8 basis points compared to 2024, but the rate of decline has narrowed [9]. - Non-interest income grew by 11.1% year-on-year, contributing to 25% of total revenue, indicating a positive trend in non-interest revenue streams [10]. Summary by Sections Financial Performance - Q1 2025 revenue and net profit growth rates were 0.4% and 2.2% respectively, with a year-on-year decline in the annualized return on average equity (ROAE) to 10.82% [4][5]. - The bank's net interest income decreased by 2.7%, while non-interest income increased by 11.1% compared to the previous year [5]. Loan and Deposit Growth - As of Q1 2025, the bank's interest-earning assets and loans grew by 6.3% and 9.8% year-on-year, respectively [6]. - The bank's loan growth was driven by high demand in key sectors, with significant increases in loans to strategic emerging industries and rural areas [7]. Asset Quality and Risk Management - The non-performing loan (NPL) ratio decreased to 1.28%, the lowest in history, with a total NPL balance of 334.6 billion CNY [11]. - The bank's provision coverage ratio was 297.8%, indicating strong risk mitigation capabilities [11]. Capital Adequacy and Valuation - The core tier 1 capital adequacy ratio stood at 11.2%, reflecting a slight decrease from the previous year [11]. - The report forecasts earnings per share (EPS) of 0.83, 0.85, and 0.87 CNY for 2025, 2026, and 2027 respectively, with corresponding price-to-book (PB) ratios of 0.68, 0.63, and 0.59 [12][13].

Investment Rating - The report maintains an "Accumulate" rating for the company [1] Core Views - The company experienced pressure on performance in Q1 2025, with a year-on-year decline in profitability [4] - Q1 2025 revenue was 2.942 billion yuan, down 8.25% year-on-year, and net profit attributable to the parent company was 36 million yuan, down 81.03% year-on-year [4] - The company plans to accelerate its opening of new hotels, with a target of 1,300 new openings in 2025 [7] Summary by Sections Financial Performance - Q1 2025 revenue from domestic hotel operations was 2.116 billion yuan, down 6.37% year-on-year [5] - The full-service hotel segment generated revenue of 59 million yuan, up 31.39% year-on-year, while the RevPAR was 192.19 yuan, down 8.30% year-on-year [5] - The limited-service hotel segment generated revenue of 2.057 billion yuan, down 7.14% year-on-year, with a RevPAR of 137.53 yuan, down 5.31% year-on-year [5] Profitability and Cost Management - The company's gross margin in Q1 2025 was 31.85%, down 3.52 percentage points year-on-year [6] - The operating profit margin for Q1 2025 was 1.2%, down 4.70 percentage points year-on-year [6] Expansion Plans - In Q1 2025, the company opened 226 new hotels, with a net increase of 97 hotels [7] - The company has a total of 13,513 hotels in operation as of the end of Q1 2025 [7] Earnings Forecast and Valuation - The forecast for net profit attributable to the parent company for 2025 has been adjusted to 1.040 billion yuan, a decrease of 12.4% from previous estimates [7] - The expected EPS for 2025 is 0.97 yuan, with corresponding P/E ratios of 25, 20, and 17 for 2025, 2026, and 2027 respectively [8]

2025 年 5 月 3 日 分析师：陈奇凡 执业证书编号：S0930523050002 021-52523819 chenqf@ebscn.com 市场数据 | 总股本(亿股) | 26.84 | | --- | --- | | 总市值(亿元)： | 145.18 | | 一年最低/最高(元)： | 4.60/8.12 | | 近 3 月换手率： | 40.63% | 公司研究 25Q1 利润环比改善，盈利水平触底回升 ——旗滨集团（601636.SH）2024 年年报及 2025 年一季报点评 买入（维持） 当前价：5.41 元 作者 分析师：孙伟风 执业证书编号：S0930516110003 021-52523822 sunwf@ebscn.com 股价相对走势 -34% -20% -7% 7% 21% 04/24 07/24 10/24 01/25 旗滨集团 沪深300 | 收益表现 | | | | | --- | --- | --- | --- | | % | 1M | 3M | 1Y | | 相对 | -3.31 | -3.43 | -32.46 | | 绝对 | -6.24 | -4.08 | ...

2025 年 5 月 3 日 公司研究 业绩具备韧性，产能外延增长可期 ——山西焦煤（000983.SZ）2024 年报及 2025 年一季报点评 要点 事件： 2025 年 4 月 28 日，公司发布了 2024 年度报告及 2025 年一季报。2024 年，公司营业收入 452.9 亿元，同比-18.4%，归母净利润 31.1 亿元，同比-54.1%， 扣非净利润 30.2 亿元，同比-55.8%；2025Q1 公司营业收入 90.3 亿元（同比 -14.5%、环比-26.0%），归母净利润 6.8 亿元（同比-28.3%、环比+159.8%）， 扣非净利润 7.3 亿元（同比-19.1%、环比+186.8%）。 风险提示：钢材需求大幅回落；焦煤进口超预期增长。 公司盈利预测与估值简表 | 指标 | 2023 | 2024 | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 55,523 | 45,290 | 43,759 | 43,909 | 44,059 | | 营业收入增长率 | -14.82% ...

Investment Rating - The report assigns a "Buy" rating to the company with a target price of 104.5, compared to the last closing price of 87.32 [1]. Core Insights - The company has established a strong presence in the lung cancer treatment sector, with a product matrix gradually taking shape, primarily centered around the drug Vomeletinib [4][5]. - Vomeletinib has rapidly gained market traction after being included in the national medical insurance directory, with projected commercial revenue of 3.5 billion in 2024 and a profit of 1.4 billion [4]. - The company is expanding its product line through collaborations and new drug developments, aiming to enhance its competitive edge in the lung cancer treatment market [5][19]. Summary by Sections Company Overview - The company has evolved into a comprehensive biopharmaceutical enterprise with capabilities in research, production, and sales since its establishment in 2004 [13][14]. - It has developed a full lifecycle drug research system, successfully launching two first-class new drugs [14]. Product Development and Pipeline - Vomeletinib is the only third-generation EGFR-TKI effective against all four types of EGFR mutations, with ongoing clinical trials for various indications [5][19]. - The company is collaborating with ArriVent to expand Vomeletinib's international market presence, which will further enhance its revenue potential [5][21]. - The introduction of new drugs like KRAS inhibitors and SHP2 inhibitors is expected to complement Vomeletinib and address treatment resistance issues [19][64]. Financial Projections - The company anticipates significant revenue growth, with projected sales of 3.56 billion in 2024, increasing to 7.45 billion by 2027, reflecting a compound annual growth rate of over 100% for Vomeletinib [8][41]. - The net profit is expected to rise from 1.43 billion in 2024 to 2.89 billion in 2027, indicating strong profitability growth [8]. Market Potential - The EGFR-TKI market in China is projected to grow significantly, with a compound annual growth rate of 34.8% from 2017 to 2022, reaching 205 billion by 2027 [46][49]. - The company is well-positioned to capture market share in the rapidly expanding lung cancer treatment sector, particularly with the increasing prevalence of EGFR mutations among patients [45][57].